 |
 |

Effect of a 1-Week Treatment With 0.5% Topical Fluorouracil on Occurrence of Actinic Keratosis After Cryosurgery
A Randomized, Vehicle-Controlled Clinical Trial
Joseph Jorizzo, MD;
Jonathan Weiss, MD;
Katharine Furst;
Christine VandePol, MD;
Sharon F. Levy, MD
Arch Dermatol. 2004;140:813-816.
Background No long-term randomized controlled clinical trial has compared the efficacy of cryosurgery alone vs cryosurgery following fluorouracil applications for the treatment of actinic keratosis.
Objective To determine the 6-month outcome of a 1-week course of 0.5% fluorouracil followed by cryosurgery.
Design Prospective, multicenter, randomized, double-blind, vehicle-controlled clinical trial performed in community and academic outpatient clinics.
Patients A total of 144 patients with 5 or more visible or palpable actinic keratoses on the face.
Interventions Topical 0.5% fluorouracil or vehicle once daily for 7 days. At the 4-week follow-up visit, residual lesions were treated with cryosurgery.
Main Outcome Measure Reduction in facial actinic keratoses from baseline to 4 weeks and 6 months.
Results At 4 weeks, mean actinic keratosis lesion count was reduced by 62.4% in the 0.5% fluorouracil group vs 28.8% in the vehicle group (P<.001), and complete clearance was achieved in 16.7% of patients in the 0.5% fluorouracil group vs 0% of those in the vehicle group (P<.001). At 6 months, mean lesion count was reduced by 67.0% in the 0.5% fluorouracil plus cryosurgery group vs 45.6% in the vehicle plus cryosurgery group (P = .01), and significantly more patients in the 0.5% fluorouracil plus cryosurgery group than in the vehicle plus cryosurgery group had complete clearance (30% vs 7.7%; P<.001).
Conclusions A 1-week course of topical 0.5% fluorouracil before cryosurgery is significantly more effective in reducing patients' numbers of actinic keratosis lesions 6 months after treatment than cryosurgery alone. The high occurrence rate of actinic keratosis lesions at 6 months suggests a need for follow-up.
From the Wake Forest University School of Medicine, Winston-Salem, NC (Dr Jorizzo); Gwinnett Clinical Research Center, Snellville, Ga (Dr Weiss); and Dermik Laboratories, Berwyn, Pa (Drs VandePol and Levy and Ms Furst). Dr Jorizzo is an occasional speaker for Dermik Laboratories, a subsidiary of Aventis Pharmaceuticals, and Dr Weiss has received research grants from Dermik Laboratories and Aventis Pharmaceuticals.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Adherence to a Topical Regimen of 5-Fluorouracil, 0.5%, Cream for the Treatment of Actinic Keratoses
Yentzer et al.
Arch Dermatol 2009;145:203-205.
FULL TEXT
5-Fluorouracil and Liquid Nitrogen Combo for Actinic Keratoses
Journal Watch Dermatology 2004;2004:3-3.
FULL TEXT
|